In addition, there was a decreasing trend of the risks of renal function decline in patients with better baseline eGFR (eGFR ≥ 90 mL/min/1.73 m 2 , HR = 0.31, 95% CI: 0.19–0.50; eGFR ≥ 60 to < 0 mL/min/1.73 m 2 , HR = 0.41, 95% CI: 0.27–0.62; eGFR ≥ 30 to < 60 mL/min/1.73 m 2 , HR = 0.66, CI: 0.44–1.00; eGFR ≥ 15 to < 30 mL/min/1.73 m 2 , HR = 0.50, CI: 0.19–1.34; p for interaction = 0.001).
← all excerpts
The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus.
1
—
—